Rifampicin and its derivatives are at the forefront of the current standard chemotherapeutic regimen for active tuberculosis; they act by inhibiting the transcription activity of prokaryotic RNA polymerase. Rifampicin is believed to interact with the b subunit of RNA polymerase. However, it has been observed that protein-protein interactions with RNA polymerase core enzyme lead to its reduced susceptibility to rifampicin. This mechanism became more diversified with the discovery of RbpA, a novel RNA polymerase-binding protein, in Streptomyces coelicolor that could mitigate the effect of rifampicin on RNA polymerase activity. MsRbpA is a homologue of RbpA in Mycobacterium smegmatis. On deciphering the role of MsRbpA in M. smegmatis we found that it interacts with RNA polymerase and increases the rifampicin tolerance levels, both in vitro and in vivo. It interacts with the b subunit of RNA polymerase. However, it was found to be incapable of rescuing rifampicin-resistant RNA polymerases in the presence of rifampicin at the respective IC 50 .
INTRODUCTION
Tuberculosis (TB) is responsible for the loss of more human lives every week than any other infectious disease. Chemotherapy for TB has resulted from the success of a handful of natural products and synthetic molecules that were tested as inhibitors for Mycobacterium tuberculosis. However, the chemotherapeutic options have been limited to a very small number of compounds, introduced 40-50 years ago, viz. rifampicin, isoniazid, pyrazinamide and ethambutol, which form the armoury of the first-line chemotherapy against TB (Nguyen & Thompson, 2006) . Although a plethora of small-molecule inhibitors have been reported over the years targeting bacterial DNA-dependent RNA polymerase, the only drug approved for clinical administration for treating TB, along with other infectious diseases, is rifampicin. Rifampicin belongs to the family of ansamycins, which were discovered in a strain of Nocardia mediterranei (Villain-Guillot et al., 2007) . Notwithstanding the efficacy of rifampicin in TB treatment, resistant mutants arise spontaneously, especially due to improper drug administration. Rifampicin resistance in all eubacterial species has been attributed to structural changes in RNA polymerase resulting from missense mutations in the rpoB gene (Jin & Gross, 1988; Miller et al., 1994) . Apart from the classical mechanism of action of rifampicin on the b subunit, another mechanism has also been proposed (Artsimovitch et al., 2005) . Rifampicin seems to be nearer to region 3 of the s-factor than expected from the crystal structure of the rifampicin-core RNA polymerase complex. This proximity could provide an explanation for the sdependence of the inhibition of transcription by rifampicin; for example, the inhibition is stronger when the polymerase uses s 70 compared with s 32 (Węgrzyn et al., 1998) .
M. tuberculosis exhibits rifampicin tolerance -a reversible physiological state involving lowered sensitivity to rifampicin -which limits bactericidal kinetics. In other words, rifampicin cannot quickly kill persistent populations of M. tuberculosis which are found in clinical disease. The long period of chemotherapy which is needed leads to poor patient compliance, and in turn, difficulties in disease control. Rifampicin-tolerant M. tuberculosis cells exhibit low but detectable levels of RNA polymerase activity in the presence of rifampicin (Hu et al., 2000) . This behaviour was thought to be due to alternative forms of RNA polymerase holoenzymes associated with various factors, leading to lowered affinity of RNA polymerase to rifampicin. Rapid purification of RNA polymerase from biomass cultured to different stages of growth (Mukherjee & Chatterji, 2008) showed that the IC 50 of rifampicin for stationary-phase RNA polymerase was double that for exponential-phase RNA polymerase. The composition of the transcription complex at the stationary phase was studied; this revealed the association of several proteins with RNA polymerase throughout the purification process, prominent among them being GroEL1, DNA polymerase 1, transcription repair coupling factor and preprotein translocase. Thus, it was speculated that in the stationary phase, RNA polymerase could be insulated from rifampicin by such associated proteins. The role of a DNA replication machinery protein, DnaA, has recently been reported (Flåtten et al., 2009 ) with respect to its in vitro interaction with RNA polymerase in Escherichia coli, and the partial protection that RNA polymerase received from rifampicin as a result of this interaction.
In an independent line of study, a new protein, RbpA, was discovered in Streptomyces coelicolor (Newell et al., 2006) . This protein can interact with RNA polymerase, causes rifampicin tolerance of RNA polymerase activity in vitro and leads to basal levels of rifampicin resistance in vivo. RbpA was earlier observed as a protein that copurifies with RNA polymerase preparations in S. coelicolor (Paget et al., 2001) . This protein was named as RbpA (RNA polymerasebinding protein). Moreover, RbpA has sequence homologues exclusively in the actinomycete family, with nearest neighbours in mycobacteria. Paget et al. (2001) discovered RbpA as a part of the s R regulon in S. coelicolor. The comparison of the upstream sequence of rbpA between S. coelicolor and M. tuberculosis revealed a strong conservation of the 210 and 235 regions, making s H a possible candidate for regulating rbpA MTB (Rv2050). Interestingly, when rbpA null mutants of S. coelicolor were transformed with the M. tuberculosis rbpA gene, the resistance to rifampicin increased from 0.75 mg ml 21 to 2 mg ml 21 in vivo, which pointed towards an analogous role of rbpA MTB . Saturation mutagenesis studies carried out on M. tuberculosis have placed rbpA MTB (Rv2050) on the list of genes needed for optimal growth (Sassetti et al., 2003) . The similarities and the speculations over mycobacterial RbpA made a compelling case for deciphering its role in mycobacteria, especially in the context of rifampicin tolerance. Bioinformatic analysis identified a homologue of rbpA MTB (Rv2050) in M. smegmatis in the form of the MSMEG_3858 product, which is 92 % identical and 100 % similar to rbpA MTB . Here we report the role of MSMEG_3858 (MsRbpA) with respect to rifampicin tolerance in mycobacteria. To the best of our knowledge, this is the first study on RbpA after that of Newell et al. (2006) .
METHODS
Bacterial strains, plasmids and growth conditions.
Mycobacterium smegmatis mc
2 155 is the wild-type strain. SM07 is a recombinant strain derived from mc 2 155, harbouring a chromosomal hexahistidine-encoding tag on the rpoC gene (Mukherjee & Chatterji, 2008 Escherichia coli strain DH5a was used for cloning experiments. The protein expression and purification experiments were carried out using E. coli strain BL21(DE3) in Luria-Bertani medium.
All plasmids used in this study are listed in Table 1 . 2 155. pJAM2 encodes an acetamide-inducible expression system used for the purification of recombinant proteins in M. smegmatis (Triccas et al., 1998) . pJAM2 was electroporated into M. smegmatis mc 2 155 competent cells and the transformants were selected on MB7H9 medium with 2 % (w/v) glucose and kanamycin. JRmc 2 155. pJAM2MsRbpA contains MSMEG_3858 cloned in pJAM2. M. smegmatis mc 2 155 competent cells were electroporated with pJAM2MsRbpA and the colonies were screened on MB7H9 medium supplemented with 2 % (w/v) glucose and kanamycin. SM0747, SM0734 and SM0748. Construction of these strains is described in the Supplementary Methods available with the online version of this paper. Table 2 ). The 367 bp amplicon was cloned in the XhoI/NdeI-digested pET21b vector (Novagen) to create pETMsRbpA. The clone was confirmed by DNA sequencing and MALDI-TOF MS from a sample obtained from in-gel trypsin digestion of the band corresponding to 14 kDa in 15 % SDS-PAGE.
Strain constructions

Jmc
pJAM2MsRbpA. Primers MsRbpJAM2f and MsRbpJAM2r (see Table  2 ) were used to amplify MSMEG_3858 from M. smegmatis genomic DNA, which was later cloned in pJAM2, pre-digested with XbaI/ BamHI. The clone was confirmed by PCR using internal primers pRbpintf and pRbpintr (see Table 2 ), specific for MSMEG_3858, as well as Western blotting using anti-MsRbpA antibody on acetamideinduced cultures.
Purification of His-tagged MsRbpA. pETMsRbpA was transformed into E. coli BL21(DE3) and after 3 h of induction with 1 mM IPTG, cells were harvested. The pellet was resuspended in 20 ml icecold lysis buffer [50 mM Tris/HCl, 5 % (v/v) glycerol, 0.1 mM EDTA, 1 M NaCl, 1 mM DTT, 6 mM b-mercaptoethanol, 1 mM imidazole, 23 mg PMSF ml 21 , 200 mg hen egg white lysozyme ml
21
, pH 7.8]. The remaining steps of the protocol were similar to the method followed by Kumar & Chatterji (2008) .
Pull-down assay for wild-type lysate of M. smegmatis over an immobilized (His) 6 MsRbpA-Ni-NTA matrix. Cells from a 24 h culture of M. smegmatis mc 2 155 were resuspended in lysis buffer [50 mM Tris/HCl, 5 % (v/v) glycerol, 0.1 mM EDTA, 1 M NaCl, 1 mM DTT, 6 mM b-mercaptoethanol, 23 mg PMSF ml 21 , 200 mg hen egg white lysozyme ml 21 , pH 7.8] and incubated in ice for 30 min with 0.2 % (w/v) sodium deoxycholate, with occasional shaking. After incubation, the suspension was subjected to sonication and French press treatment. The lysate was centrifuged and the supernatant was treated with 0.6 % (v/v) polyethylenimine P and centrifuged. The resulting pellet was extracted with 1 M NaCl in TGEB buffer [10 mM Tris/HCl, 5 % (v/v) glycerol, 0.1 mM EDTA, 6 mM b-mercaptoethanol] followed by 50 % ammonium sulfate precipitation. The pellet was resuspended in TGEB containing 1 M NaCl and 1 mM imidazole and kept for binding with a Ni-NTA matrix, pre-equilibrated with purified (His) 6 MsRbpA. After 6 h incubation on a rotary shaker at 4 uC, the Ni-NTA matrix was washed with 100 column volumes of TGEB buffer containing 0.6 M NaCl and 10 mM imidazole. (His) 6 MsRbpA and associated proteins were eluted in TGEB buffer with 400 mM NaCl and 250 mM imidazole.
Reconstitution of a heterologous mycobacterial core RNA polymerase. The various subunits of core RNA polymerase were purified as described in the Supplementary Methods. The reconstitution was carried out by dialysing 2 mg purified M. smegmatis RNA polymerase a subunit (50 nmol 
The bound proteins were eluted with TGEB+0.4 M NaCl+250 mM imidazole. The eluted fractions were dialysed against TGED+0.4 M NaCl for 12 h in two batches to remove imidazole. This fraction was subjected to another dialysis in TGED+0.15 M NaCl. The final dialysed fraction was loaded onto a heparin-Sepharose column (prequilibrated with TGED+0.15 M NaCl) and kept for binding for 6 h. The column was washed with five column volumes of TGED+0.15 M NaCl buffer. The proteins were eluted with TGED+0.6 M NaCl buffer. The eluted fractions were then analysed for their purity by 10 % SDS-PAGE and subsequently assayed for RNA synthesis activity.
Promoter-specific single-round gel-based transcription assay.
The M. tuberculosis rel promoter was amplified from pVJP16 (Jain et al., 2005) using primers PrelF and PrelR ( Table 2 ). The amplicon thus obtained was used as a template for the single-round promoter-specific transcription assay. Purified s A (200 nM) from M. tuberculosis was incubated with reconstituted core RNA polymerase (100 nM) in molar ratio 2 : 1 in transcription buffer [40 mM Tris/HCl, 10 mM MgCl 2 , 75 mM KCl, 0.1 mM EDTA, 0.1 mM DTT, 14 mM b-mercaptothanol, 0.025 mg ml 21 BSA (nuclease free)] at 37 uC for 10 min. The DNA template rel amplicon (10 nM) was then added at a 0.1 molar ratio to RNA polymerase and a further incubation of 37 uC for 5 min was carried out. Finally, the NTP mix comprising 0.15 mM ATP, 0.15 mM GTP, 0.15 mM CTP, 0.05 mM UTP, 2 mCi (74 kBq) [ 32 P]UTP and 200 mg heparin ml 21 was added, followed by incubation for 30 min at 37 uC. The reaction was stopped by addition of stop solution (5 mM EDTA and 100 mg E. coli tRNA ml
). The transcription products were subjected to 10 % denaturing PAGE in the presence of 6 M urea and analysed by phosphorimager (FLA2000; Fujifilm) (Chowdhury et al., 2007) .
In the transcription reactions involving the addition of rifampicin, the core RNA polymerase, s A and rifampicin were incubated together in transcription assay buffer at 37 uC for 10 min before the addition of DNA, NTPs and heparin. In the transcription reactions involving the presence of MsRbpA, the core RNA polymerase, s A and rifampicin were incubated together in transcription assay buffer at 37 uC for 10 min and then MsRbpA was added to the mix followed by incubation at 37 uC for 5 min. This was followed by addition of DNA, NTP and heparin in order to complete the transcription reaction.
Cross-linking of MsRbpA with RNA polymerase using the heterobifunctional cross-linker sulfo-HSAB. With the objective of determining the binding partner of MsRbpA on RNA polymerase, a chemical cross-linking reaction was carried out between MsRbpA and M. smegmatis RNA polymerase. Sulfo-HSAB (N-hydroxysulfosuccinimidyl-4-azidobenzoate; Pierce) was used as a cross-linker. M. smegmatis core RNA polymerase was purified from a 30 h culture and dialysed in PBS (pH 7.8). (His) 6 MsRbpA labelled with [ 35 S]methionine was also purified and dialysed against PBS (pH 7.8).
35
S-labelled (His) 6 MsRbpA (70 mM) was mixed with 50-fold molar excess of sulfo-HSAB dissolved in PBS (pH 7.8). After incubation at 37 uC in the dark for 30 min, the mix was loaded on a Sephadex-G25 column to separate unreacted sulfo-HSAB from the protein. The labelling of MsRbpA with sulfo-HSAB was followed by monitoring the increase in A 260 as a measure of Nhydroxysuccinimide (NHS) ester hydrolysis caused as a result of labelling. The protein was detected in the void volume by scintillation counting. The labelled MsRbpA was incubated with fivefold molar excess of RNA polymerase at 37 uC for 30 min followed by exposure to 254 nm UV light for 8 min. The reaction mix was immediately subjected to 12 % SDS-PAGE, and the complexes formed as a result of chemical cross-linking were detected with anti-MsRbpA antibodies, and antibodies against the M. tuberculosis b9, M. tuberculosis b, M. smegmatis a and M. smegmatis v subunits of RNA polymerase (subsequently referred to as anti-M. tuberculosis b9, anti-M. tuberculosis b, anti-M. smegmatis a and anti-M. smegmatis v antibodies).
RESULTS
MsRbpA is highly conserved in pathogenic and non-pathogenic mycobacterial species
RbpA was discovered as a protein co-eluting with RNA polymerase during purification from S. coelicolor (Paget et al., 2001) . The characterization of this protein for its role in rifampicin resistance in S. coelicolor was reported later by the same group (Newell et al., 2006) . Bioinformatic analysis identified an RbpA homologue in M. smegmatis with accession number MSMEG_3858, which was 92 % identical to the M. tuberculosis relative Rv2050 (Fig. 1) . Further analysis revealed that MsRbpA homologues are highly conserved in mycobacterial species (Fig. 2) . Another conspicuous feature is the occurrence of a homologue of RbpA in Nocardia farcinica ( Supplementary Fig. S1 ), the only sequenced genome from the genus Nocardia, which includes the rifampicin producer, N. rifamycinica. This could be a possible defence mechanism that Nocardia might use against its own metabolite rifampicin.
MsRbpA can interact with RNA polymerase
MsRbpA was tagged with a stretch of six histidines at the C-terminus by cloning MSMEG_3858 in pET21b (pre- A. Dey and others digested with NdeI and XhoI). The protein purified as MsRbpA was confirmed by DNA sequencing and MALDI-TOF MS ( Supplementary Fig. S2 , Supplementary Table  S1 ). The (His) 6 MsRbpA was immobilized on a Ni-NTA matrix (Qiagen); wild-type M. smegmatis lysate fractionated with 50 % ammonium sulfate was loaded on the matrix, and left for binding overnight at 4 u C. The eluates obtained showed the presence of RNA polymerase (Fig.  3a) . The eluates were screened for RNA polymerase subunits using anti-M. tuberculosis b9 and anti-M. tuberculosis b antibody (Fig. 3b) . However, a pull-down assay on crude cell lysate is not the best way to establish protein-protein interaction (Mackay et al., 2007) . Therefore, we repeated the pull-down assay using a pure RNA polymerase from wild-type M. smegmatis (Fig. 3c,  Supplementary Fig. S3 ). The pull-down assay using purified RNA polymerase reconfirmed the interaction between MsRbpA and RNA polymerase and also indicated that this interaction was not mediated by other proteins present in the cell lysate.
MsRbpA rescues RNA polymerase from the inhibitory effect of rifampicin
In order to test the role of MsRbpA in rescuing RNA polymerase from the inhibitory effect of rifampicin, we reconstituted core RNA polymerase comprising pure b9, b, a and v subunits from either M. tuberculosis or M. smegmatis ( Supplementary Fig. S4 ). Due to the greater than 90 % identity in different subunits of RNA polymerase across the species of mycobacteria, the reconstituted enzyme is the same from either of the species. The purpose of reconstitution was to rule out any possibility of other proteins which might co-purify with RNA polymerase and influence the results. We tested those concentrations of rifampicin where the transcription activity is completely inhibited and challenged the same conditions with the addition of MsRbpA (Fig. 4a) . We found that MsRbpA could rescue the in vitro activity of RNA polymerase in a promoter-specific single-round transcription assay, carried out from the rel promoter of M. tuberculosis (Jain et al., 2005) . Transcription occurred even at 100 mM rifampicin, when the molar ratio of RNA polymerase to MsRbpA was kept at 1 : 2. When we increased the molar ratio of RNA polymerase to MsRbpA from 1 : 0.5 to 1 : 3 at constant rifampicin concentration of 40 mM (Fig. 4b) , we observed that the use of threefold molar excess of MsRbpA restored the in vitro activity of RNA polymerase to the normal level.
Overexpression of MsRbpA in M. smegmatis increases rifampicin tolerance
We cloned MsRbpA under the acetamidase promoter in pJAM2 (Triccas et al., 1998) and electroporated the , while the strain carrying pJAM2 was incapable of growing at these concentrations (Fig. 5a) 155). The MsRbpA-overexpressing strain showed smaller colonies compared to the vector-carrying strain (Fig.   5b ). We also carried out growth-dependent Western blot analysis using anti-MsRbpA antibody on wild-type M. smegmatis lysates to determine the levels of MsRbpA (Fig.  5c ). The level of MsRbpA increased in stationary-phase cultures of M. smegmatis. However, the level of expression was much less as compared to the RNA polymerase a subunit, which was taken as the loading control.
MsRbpA interacts with the b subunit of RNA polymerase
The chemical cross-linker HSAB had been previously used to locate the binding site of the v subunit to the b9 subunit on RNA polymerase (Gentry & Burgess, 1993) . We used the same strategy to locate the binding of MsRbpA on M. smegmatis core RNA polymerase purified from 30 h cultures of M. smegmatis SM07. The hetero-bifunctional cross-linker sulfo-HSAB is modified by the attachment of a sulfo group compared to the free HSAB used by Gentry & Burgess (1993) , rendering it water soluble. Cross-linking of MsRbpA to RNA polymerase involved two steps: derivatizing [ Supplementary Fig. S5a ) with sulfo-HSAB, followed by incubating the derivatized MsRbpA with core RNA polymerase and exposing the mixture to UV light ( Supplementary Fig. S5b) by observing the increase in A 260 due to release of NHS ester ( Supplementary Fig. S5c ).
[ S]MsRbpA-AB) were exposed to UV light (254 nm) there was formation of highly reactive phenylnitrene, which created covalent linkages with a variety of molecules. Such cross-linked products to RNA polymerase subunits were detected due to the formation of a covalent adduct on SDS gel which was identified by both anti-MsRbpA and anti-RNA polymerase subunit antibodies. The observed product was expected to have a size approximating the molecular mass of MsRbpA plus that of the specific subunit. The crosslinking reactions were carried out in the dark, according to the manufacturer's instructions. The products of crosslinking were probed with anti-MsRbpA, anti-M. tuberculosis b, anti-M. tuberculosis b9, anti-M. smegmatis a and anti-M. smegmatis v antibodies. We observed a shift in the molecular mass of the b subunit after the photo-crosslinking reaction, in agreement with the shift in the molecular mass of the MsRbpA band (lanes 5 and 6 in Fig. 6a ; lane 2 in Fig. 6b) . The Western analysis with anti-M. tuberculosis b9, anti-M. smegmatis a and anti-M. smegmatis v antibodies did not show any shift in band position (Fig. 6c, d ).
MsRbpA does not restore the activity of Rif R RNA polymerases in the presence of rifampicin at the IC 50
As both rifampicin and MsRbpA bind to the b subunit of RNA polymerase, we determined the effect of MsRbpA on an RNA polymerase purified from a rifampicin-resistant (Rif R ) strain of M. smegmatis. We generated Rif R mutants of M. smegmatis SM07 by serial culturing of the strain from lower (5 mg ml
21
) to higher (50 mg ml
) concentrations of rifampicin ( Supplementary Fig. S6a ). After scoring the Rif R strains for resistance to 100, 200, 300 and 400 mg rifampicin ml 21 ( Supplementary Fig. S6b ), we checked whether the strains undergo reversion in the absence of antibiotic ( Supplementary Fig. S6c, d ). The selected strains were named as SM0747 (MIC of rifampicin~200-300 mg ml 21 ), SM0734 (MIC of rifampicin~300-400 mg ml 21 ) and SM0748 (MIC of rifampicin .400 mg ml
). The Rif R strains were also grown in MB7H9 broth and their growth curves were recorded at different concentrations of rifampicin ( Supplementary Fig. S6e ). They were characterized for the rpoB mutations by sequencing amplicons obtained using primers R3CF and R3CR (Table 2) on genomic DNA of M. smegmatis strains SM07, SM0747, SM0734 and SM0748. DNA sequencing was carried out by cycle sequencing using the BigDye Terminator Cycle Sequencing kit v3.0 (Applied Biosystems) and was analysed on an ABI3100 Genetic Analyser (Applied Biosystems). To detect the sequence variants in the Rif R clusters of the rpoB gene, we compared the SM07 sequence with those of SM0747, SM0734 and SM0748 using CLUSTAL W 2 (http:// www.ebi.ac.uk/Tools/clustalw2/index.html). The mutations were scored as D432Y (in the case of SM0747) and S447L (in the case of SM0734 and SM0748) ( Supplementary Fig. S6f ). The results of the Rif R mutations are in agreement with those obtained by Jin & Gross (1988) in E. coli. The IC 50 (concentration equivalent to the minimum concentration required for 50 % inhibition of multiple-round transcription activity) of rifampicin for the ; plate C, 10 mg ml
; plate D, 20 mg ml
; plate E, 40 mg ml rifampicin-sensitive RNA polymerase from SM07 was 0.05 mg ml
. The RNA polymerases purified from these strains ( Supplementary Fig. S6g) Supplementary Fig. S6h ).
DISCUSSION
The work on RbpA in S. coelicolor by Newell et al. (2006) laid the foundation for the novel mechanism of protection of RNA polymerase from the classical inhibitor rifampicin. Whether protein-protein interactions within the transcription machinery ultimately lead to the rifampicin tolerance is an important consideration. We have already mentioned that differential sensitivity to rifampicin of core RNA polymerase-s 70 or -s 32 complex (Węgrzyn et al., 1998) may arise from altered conformation of the transcription machinery, although it was not demonstrated clearly. Previous proteomic analyses by us indicated that in stationary phase, rifampicin binding to the enzyme is blocked by several proteins (Mukherjee & Chatterji, 2008 treatment was obtained when mRNA transcripts were detected after treatment of this organism with rifampicin (Hu et al., 2000) , further raising the question of whether the stress-induced changes in the proteome lead to insulation of mycobacterial RNA polymerase against rifampicin.
In this study we have attempted to dissect the role of MsRbpA with respect to its ability to confer rifampicin tolerance to RNA polymerase in mycobacteria. Our findings are summarized below.
(a) The interaction between MsRbpA and reconstituted RNA polymerase mitigates the inhibition of transcription even at 100 mM rifampicin, in an M. tuberculosis rel promoter-specific single-round transcription assay. Table S3 ), indicating that perhaps the effect of MsRbpA is not promoter specific.
(c) MsRbpA acts by binding to the b subunit of RNA polymerase. As the b subunit is the site of action of rifampicin, we checked the action of MsRbpA on Rif R RNA polymerase. For that purpose we developed Rif R mutants of M. smegmatis SM07 and mapped the mutation sites on the Rif R clusters of the b subunit. However, we observed no change in the IC 50 values in these cases, even with an 8 : 1 molar ratio of MsRbpA : RNA polymerase.
At this point, we do not know where exactly MsRbpA binds the b subunit. However, our results indicate that the binding site may overlap with the rifampicin-binding domain. Such a proposition seems reasonable, as we know that there are four such domains along the length of the b subunit (Jin & Gross, 1988) . The mode of action of MsRbpA in relieving RNA polymerase from rifampicin inhibition could be by shielding the polymerase against rifampicin or causing a conformational change in the binding site of rifampicin so that the interaction between RNA polymerase and rifampicin cannot take place. It should be mentioned here that we were unable to detect any interaction between MsRbpA and rifampicin in vitro (data not shown).
It was also intriguing why MsRbpA did not have a similar rifampicin rescue effect on a Rif R RNA polymerase as it had on a Rif S RNA polymerase. Such behaviour makes it tempting to speculate upon a kind of switching in the behaviour of the cell in response to rifampicin when RNA polymerase evolves from a Rif S to a Rif R form, in which case the role of MsRbpA in providing phenotypic tolerance to rifampicin becomes redundant. Thus, it appears that MsRbpA plays a role in protecting the Rif S RNA polymerase when the cell attempts to evolve into a genetically Rif R strain. . Thus, our in vivo data corroborated the in vitro data on MsRbpA obtained from the transcription assays.
(e) Microarray data of Murphy & Brown (2007) revealed that Rv2050 was upregulated under conditions of aerated starvation, starvation under 50 % dissolved oxygen, and in vitro hypoxia (Wayne model; Wayne & Hayes, 1996) , as well as in mouse macrophages. Rv2050 was also upregulated under conditions of heat shock, diamide stress and dormant stage (AstraZeneca R&D, Bangalore, personal communication). Thus, it appears that Rv2050 is induced by multiple stress conditions. MsRbpA (MSMEG_3858) (which is 100 % similar to Rv2050) was also found to be upregulated in stationary-phase cultures of M. smegmatis. It will be interesting to find out whether MsRbpA has any effect on cells other than those described.
